Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pre-miR-125a-5p mimic is a synthetic, double-stranded RNA molecule designed to replicate the biological activity of the endogenous tumor suppressor microRNA, miR-125a-5p. In various malignancies, including cervical carcinoma, miR-125a-5p expression is frequently downregulated, which facilitates tumor progression. By introducing this mimic, researchers can restore miR-125a-5p levels, which subsequently binds to the 3' untranslated regions (UTRs) of specific target mRNAs such as MARK1 (Microtubule Affinity Regulating Kinase 1) and VEGF (Vascular Endothelial Growth Factor). This binding leads to mRNA degradation or translational repression, effectively downregulating these proteins and resulting in cell-cycle arrest, inhibition of proliferation, and the induction of apoptosis. It is primarily utilized as a research tool to investigate miRNA-mediated gene regulation and potential therapeutic strategies in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pre-miR-125a-5p mimic.